Novavax, Inc. (NVAX)

Market Cap	1.05B
Revenue (ttm)	1.06B
Net Income (ttm)	341.75M
Shares Out	162.50M
EPS (ttm)	2.07
PE Ratio	3.12
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,033,740
Open	6.25
Previous Close	6.22
Day's Range	6.25 - 6.54
52-Week Range	5.01 - 11.55
Beta	2.30
Analysts	Hold
Price Target	10.78 (+66.62%)
Earnings Date	Nov 6, 2025

About NVAX

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 5, 1995
• Employees: 952
• Stock Exchange: NASDAQ
• Ticker Symbol: NVAX
• Website: https://www.novavax.com

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Analyst Summary

According to 9 analysts, the average rating for NVAX stock is "Hold." The 12-month stock price target is $10.78, which is an increase of 66.62% from the latest price.

Price Target

$10.78

(66.62% upside)

Analyst Consensus: Hold